AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31863269 — intervention group
Group type: COMPARATOR
Intervention: Emotional disclosure writing condition (EMO group)
Number of subjects: 118
Study 31863269 — intervention group
Group type: COMPARATOR
Intervention: Self-regulation writing condition (SR group)
Number of subjects: 118
Study 31863269 — intervention group
Group type: COMPARATOR
Intervention: Neutral control condition with no writing tasks (CON group)
Number of subjects: 118
Study 31039158 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) program
Number of subjects: 941
Study 31039158 — intervention group
Group type: COMPARATOR
Intervention: No conditional cash transfer (CCT) program
Number of subjects: 941
Study 28834360 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS inhibitors
Number of subjects: 3848
Study 25345681 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily sessions of music-guided slow-breathing (<10 breaths/min) for 30 minutes
Number of subjects: 37
Study 25345681 — intervention group
Group type: COMPARATOR
Intervention: Simple relaxation (control)
Number of subjects: 37
Study 23480646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ronnie Gardiner Rhythm and Music (RGRM™) Method
Number of subjects: 18
Study 23480646 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 20798190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound collapse pressure (UCP)
Number of subjects: 0
Study 20798190 — intervention group
Group type: EXPERIMENTAL
Intervention: External jugular venous pressure (JVPEXT)
Number of subjects: 0
Study 20798190 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular venous pressure (JVPINT)
Number of subjects: 0
Study 18623908 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg twice a day)
Number of subjects: 1076
Study 18623908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1076
Study 18623908 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 1076
Study 16860173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg QD
Number of subjects: 554
Study 16860173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg QD
Number of subjects: 554
Study 16860173 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 200 microg BID
Number of subjects: 554
Study 12640507 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (2 to 4 mg/day)
Number of subjects: 40
Study 12640507 — intervention group
Group type: COMPARATOR
Intervention: Captopril (75 to 150 mg/day)
Number of subjects: 40
Study 10584125 — intervention group
Group type: EXPERIMENTAL
Intervention: Curative radiotherapy for localized prostate cancer in elderly patients
Number of subjects: 59
Study 10584125 — intervention group
Group type: COMPARATOR
Intervention: Curative radiotherapy for localized prostate cancer in younger patients
Number of subjects: 59
Study 9112715 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Satisfaction measure at 7 weeks
Number of subjects: 219
Study 9112715 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom Satisfaction measure at 1 year
Number of subjects: 219
Study 9112715 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of poor outcomes at 7 weeks
Number of subjects: 219
Study 9112715 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of poor outcomes at 1 year
Number of subjects: 219
Study 1831633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg, three intravenous doses 4-hourly)
Number of subjects: 0
Study 1831633 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (2.0 mg/kg, six intravenous doses)
Number of subjects: 0
Study 1831633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Ondansetron (16 mg t.d.s.)
Number of subjects: 0
Study 1831633 — intervention group
Group type: COMPARATOR
Intervention: Oral Placebo
Number of subjects: 0
Study 1831633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (subsequent courses)
Number of subjects: 0
Study 1831633 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 1831633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 0
Study 6346845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine (mean total daily dose of 830 mg +/- 318 mg, dosing every 8 hours)
Number of subjects: 39
Study 6346845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmozine
Number of subjects: 39
Study 29083986 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 150
Study 29083986 — intervention group
Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 150
Study 27396224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg/kg (Group K, n = 91)
Number of subjects: 183
Study 27396224 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group P, n = 92)
Number of subjects: 183
Study 24210534 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief integrated intervention (BI)
Number of subjects: 284
Study 24210534 — intervention group
Group type: EXPERIMENTAL
Intervention: BI plus 9 further sessions with integrated-focus
Number of subjects: 284
Study 24210534 — intervention group
Group type: EXPERIMENTAL
Intervention: BI plus 9 further sessions with alcohol-focus
Number of subjects: 284
Study 24210534 — intervention group
Group type: EXPERIMENTAL
Intervention: BI plus 9 further sessions with depression-focus
Number of subjects: 284
Study 24210534 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer interventions
Number of subjects: 284
Study 24210534 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 284
Study 22143524 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg loading dose followed by 50 mg every 12 h for a minimum of 7 days)
Number of subjects: 61
Study 20337827 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05%
Number of subjects: 0
Study 18545212 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% Mupirocin nasal lavage
Number of subjects: 16
Study 15729063 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colonic resection with fast-track rehabilitation
Number of subjects: 60
Study 15729063 — intervention group
Group type: COMPARATOR
Intervention: Open colonic resection with fast-track rehabilitation
Number of subjects: 60
Study 15729063 — intervention group
Group type: COMPARATOR
Intervention: Open colonic resection
Number of subjects: 60
Study 15729063 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colonic resection
Number of subjects: 60
Study 12759479 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery
Number of subjects: 1218
Study 12759479 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1218
Study 9571385 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPD+
Number of subjects: 0
Study 9571385 — intervention group
Group type: COMPARATOR
Intervention: AABS+
Number of subjects: 0
Study 9571385 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPD+ (180 days treatment)
Number of subjects: 0
Study 9571385 — intervention group
Group type: COMPARATOR
Intervention: AABS+ (180 days treatment)
Number of subjects: 0
Study 9571385 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPD+ (90 days treatment)
Number of subjects: 0
Study 9571385 — intervention group
Group type: COMPARATOR
Intervention: AABS+ (90 days treatment)
Number of subjects: 0
Study 7887657 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiluminescence microscopy (ELM)
Number of subjects: 19
Study 2220877 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 100 mu/kg body weight three times/week subcutaneously
Number of subjects: 11
Study 2220877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2220877 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 150 mu/kg three times/week after 12 weeks of placebo
Number of subjects: 11
Study 646969 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic oestrogen (ethinyloestradiol)
Number of subjects: 9
Study 646969 — intervention group
Group type: COMPARATOR
Intervention: Natural oestrogen (oestriol succinate)
Number of subjects: 9
Study 31757635 — intervention group
Group type: EXPERIMENTAL
Intervention: Black walnuts (BW) meal
Number of subjects: 30
Study 31757635 — intervention group
Group type: EXPERIMENTAL
Intervention: English walnuts (EW) meal
Number of subjects: 30
Study 31757635 — intervention group
Group type: COMPARATOR
Intervention: Control (butter) meal
Number of subjects: 30
Study 28746521 — intervention group
Group type: EXPERIMENTAL
Intervention: Playful workshops (8 sessions)
Number of subjects: 79
Study 26014295 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapy (ADT) with radiotherapy (RT)
Number of subjects: 1205
Study 26014295 — intervention group
Group type: COMPARATOR
Intervention: Androgen-deprivation therapy (ADT) alone
Number of subjects: 1205
Study 23217981 — intervention group
Group type: COMPARATOR
Intervention: Above-elbow cast (AEC) without percutaneous fixation
Number of subjects: 128
Study 23217981 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-elbow cast (AEC) with percutaneous fixation using Kirschner wires
Number of subjects: 128
Study 22008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking prevalence in males (35.9%)
Number of subjects: 7003
Study 22008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking prevalence in age group 30-49 years
Number of subjects: 7003
Study 22008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smokers among smokers
Number of subjects: 7003
Study 22008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular flavor cigarette usage among smokers
Number of subjects: 7003
Study 22008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempts to quit smoking among smokers
Number of subjects: 7003
Study 22008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods of quitting smoking
Number of subjects: 7003
Study 22008927 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily media habits of smokers
Number of subjects: 7003
Study 19629378 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure hemorrhoidectomy
Number of subjects: 80
Study 19629378 — intervention group
Group type: COMPARATOR
Intervention: Closed Ferguson hemorrhoidectomy
Number of subjects: 80
Study 17892034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral dydrogesterone (5 mg daily)
Number of subjects: 59
Study 17892034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transdermal hormonal therapy with 17beta‐estradiol (0.05 mg/24 hours) and oral medroxyprogesterone (5 mg daily)
Number of subjects: 59
Study 17892034 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 59
Study 15478054 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis
Number of subjects: 49
Study 11682036 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon plus amantadine
Number of subjects: 143
Study 11682036 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 143
Study 9459623 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyroid after 6 months of methimazole
Number of subjects: 88
Study 9459623 — intervention group
Group type: EXPERIMENTAL
Intervention: Euthyroid at drug withdrawal
Number of subjects: 88
Study 9459623 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 88
Study 9459623 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapsing forms of disease
Number of subjects: 88
Study 7491892 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried onions (rich in quercetin glucosides) equivalent to 89 mg aglycone
Number of subjects: 9
Study 7491892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure quercetin rutinoside equivalent to 100 mg aglycone
Number of subjects: 9
Study 7491892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure quercetin aglycone equivalent to 100 mg
Number of subjects: 9
Study 7491892 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 9
Study 2128072 — intervention group
Group type: COMPARATOR
Intervention: EDTA test
Number of subjects: 28
Study 2128072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose and EDTA tests
Number of subjects: 28
Study 2128072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EDTA and sugar tests
Number of subjects: 28
Study 2128072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose-mannitol test
Number of subjects: 28
Study 386676 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 290
Study 386676 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 290
Study 386676 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 290
Study 31228675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous intralipid (2 doses of 20% solution, 4 ml diluted in 250 ml normal saline)
Number of subjects: 105
Study 28338620 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure and privacy-preserving navigation scheme using vehicular spatial crowdsourcing based on fog-based VANETs
Number of subjects: 0
Study 28338620 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptographic primitives including Elgamal encryption algorithm, AES, randomized anonymous credentials, and group signatures
Number of subjects: 0
Study 24742182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints in combination with distal acupoint
Number of subjects: 164
Study 24742182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints in combination with distal non-acupoint
Number of subjects: 164
Study 24742182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local non-acupoints in combination with distal acupoint
Number of subjects: 164
Study 24742182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local non-acupoints in combination with distal non-acupoint
Number of subjects: 164
Study 22404057 — intervention group
Group type: EXPERIMENTAL
Intervention: pH‐stat management
Number of subjects: 9
Study 22404057 — intervention group
Group type: COMPARATOR
Intervention: alpha‐stat management
Number of subjects: 9
Study 20097934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 0
Study 20097934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 0
Study 20097934 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (single and multiple dosing)
Number of subjects: 0
Study 19068724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting one week after TURBT (Group A)
Number of subjects: 54
Study 19068724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of epirubicin (40 mg in 40 ml saline) once every two weeks for 3 months starting 6 months after TURBT (Group B)
Number of subjects: 54
Study 15854872 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated cognitive-behavioral (RCB) treatment
Number of subjects: 28
Study 15854872 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral (SB) treatment
Number of subjects: 28
Study 12814527 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 3 mg vaginal pessary in two doses 6 hourly
Number of subjects: 200
Study 12814527 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic saline infusion (EASI) with simultaneous intravenous oxytocin infusion for 12 hours
Number of subjects: 200
Study 10661762 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated video image analysis system
Number of subjects: 110
Study 10661762 — intervention group
Group type: COMPARATOR
Intervention: Normal postures (control group)
Number of subjects: 110
Study 10661762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient postures (intervention group)
Number of subjects: 110
Study 7577616 — intervention group
Group type: EXPERIMENTAL
Intervention: University hospitals (n = 13)
Number of subjects: 574
Study 7577616 — intervention group
Group type: EXPERIMENTAL
Intervention: Major county hospitals (n = 25)
Number of subjects: 574
Study 7577616 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor county hospitals (n = 61)
Number of subjects: 574
Study 7577616 — intervention group
Group type: COMPARATOR
Intervention: All hospital categories
Number of subjects: 574
Study 2246997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum
Number of subjects: 0
Study 2246997 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent programmes including counselling and ongoing follow up and support with nicotine chewing gum
Number of subjects: 0
Study 2246997 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine preparation
Number of subjects: 0
Study 2246997 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (oral or transdermal)
Number of subjects: 0
Study 2246997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7425917 — intervention group
Group type: EXPERIMENTAL
Intervention: 8‐tenths percent tropicamide with 5% phenylephrine
Number of subjects: 0
Study 7425917 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of the concentration of either component
Number of subjects: 0
Study 7425917 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of the tropicamide concentration
Number of subjects: 0
Study 7425917 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drop of the optimal combination
Number of subjects: 0
Study 7425917 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 drops of the optimal combination
Number of subjects: 0
Study 31556165 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive prenatal diagnosis technique for spinal muscular atrophy
Number of subjects: 27
Study 30636729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling without eliciting local twitch response (LTR)
Number of subjects: 26
Study 30636729 — intervention group
Group type: COMPARATOR
Intervention: Dry needling with eliciting local twitch response (LTR)
Number of subjects: 26
Study 27930393 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention addressing fear-avoidance beliefs
Number of subjects: 240
Study 27930393 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 240
Study 25557838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg daily prophylaxis)
Number of subjects: 64
Study 25557838 — intervention group
Group type: COMPARATOR
Intervention: Trivalent split virus influenza vaccine
Number of subjects: 64
Study 25557838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both zanamivir and vaccine
Number of subjects: 64
Study 25557838 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 64
Study 25557838 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to family members and patients with ARI
Number of subjects: 64
Study 24254567 — intervention group
Group type: EXPERIMENTAL
Intervention: In‐Out technique, with cortical fixation and Interference screw
Number of subjects: 45
Study 24254567 — intervention group
Group type: COMPARATOR
Intervention: Out‐In technique, metal cortical fixation on the femur and tibia
Number of subjects: 45
Study 21462363 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based C-ACT
Number of subjects: 173
Study 21462363 — intervention group
Group type: COMPARATOR
Intervention: Paper-based C-ACT
Number of subjects: 173
Study 21462363 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based ACT
Number of subjects: 173
Study 21462363 — intervention group
Group type: COMPARATOR
Intervention: Paper-based ACT
Number of subjects: 173
Study 21462363 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based version preference
Number of subjects: 173
Study 19330567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 91
Study 19330567 — intervention group
Group type: COMPARATOR
Intervention: Oral iron sulphate
Number of subjects: 91
Study 17194858 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intervention group
Number of subjects: 1614
Study 17194858 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intervention group
Number of subjects: 1614
Study 17194858 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1614
Study 17194858 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1614
Study 15173775 — intervention group
Group type: EXPERIMENTAL
Intervention: QBS algorithm
Number of subjects: 422
Study 15173775 — intervention group
Group type: EXPERIMENTAL
Intervention: BP-SPECT algorithm
Number of subjects: 422
Study 15173775 — intervention group
Group type: COMPARATOR
Intervention: QBS
Number of subjects: 422
Study 15173775 — intervention group
Group type: COMPARATOR
Intervention: BP-SPECT
Number of subjects: 422
Study 11465336 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of placebo gel (Group I)
Number of subjects: 60
Study 11465336 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 2% lidocaine gel (Group II)
Number of subjects: 60
Study 11465336 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 2% lidocaine gel (Group III)
Number of subjects: 60
Study 9766721 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorectal coil (ERC) at 60, 100, and 140 ml balloon inflation
Number of subjects: 21
Study 9766721 — intervention group
Group type: COMPARATOR
Intervention: Pelvic phased array (PPA) coil
Number of subjects: 21
Study 8143427 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state (after a meal containing 80 g of fat and 80 g of carbohydrate)
Number of subjects: 10
Study 2974418 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'dFUR (doxifluridine) 2 g.m-2
Number of subjects: 6
Study 2974418 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'dFUR (doxifluridine) 4 g.m-2
Number of subjects: 6
Study 2974418 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'dFUR (doxifluridine)
Number of subjects: 6
Study 30102652 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 1200 mg/day
Number of subjects: 0
Study 30102652 — intervention group
Group type: COMPARATOR
Intervention: Control group (not taking fluconazole)
Number of subjects: 0
Study 27118223 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone camera (iPhone 5)
Number of subjects: 440